	US 12,102,660 B2
	Association of N-acetylcysteine and colistin for use in bacterial infections
Lucia Pallecchi, Colle di Val d'Elsa (IT); Francesco Sergio, Bresso (IT); and Gian Maria Rossolini, Siena (IT)
Assigned to Zambon S.P.A., Bresso (IT)
Filed by Zambon S.P.A., Bresso (IT)
Filed on May 20, 2022, as Appl. No. 17/664,232.
Application 17/664,232 is a division of application No. 16/487,227, granted, now 11,382,948, previously published as PCT/EP2018/054611, filed on Feb. 26, 2018.
Claims priority of application No. 17158241 (EP), filed on Feb. 27, 2017.
Prior Publication US 2022/0370549 A1, Nov. 24, 2022
Int. Cl. A61K 38/12 (2006.01); A61K 31/164 (2006.01); A61K 31/198 (2006.01); A61P 31/04 (2006.01)

CPC A61K 38/12 (2013.01) [A61K 31/198 (2013.01); A61P 31/04 (2018.01)]

11 Claims

1. A method of restoring susceptibility to antibiotic treatment in colistin-resistant S. maltophilia and colistin-resistant A. baumannii strain during or after bacterial infection caused by said one or more pathogens in patients in need thereof, said method comprising

administering to said patients a pharmaceutically effective amount of a synergistic pharmacological association consisting of N-acetylcysteine (NAC) and a carrier added on to colistin, wherein in said synergistic pharmacological association NAC is present in an amount from 1.6 mg/ml to 8 mg/ml and colistin is present in an amount from 2 μg/ml to 8 μg/ml.